Davis emphasizes that many of his male patients report not only a decrease in appetite but also an increased ability to stick to healthier eating habits
Larsen also noted that Marty Makary, M.D., President Donald Trump's pick to lead the FDA, will have "influence over the enforcement of semaglutide compounding and personalization efforts." Makary is an executive at Sesame, another telehealth company that connects consumers with physicians to prescribe compounded weight loss drugs
This is a serious problem for several reasons: Muscle loss slows your resting metabolic rate, making it harder to keep weight off after stopping the medication Reduced muscle mass increases the risk of falls, fractures, and loss of physical function particularly in older adults The skinny fat phenomenon normal BMI but high body fat percentage is a real outcome of poorly managed GLP-1 use The solution is not to avoid GLP-1 medications
All medications meet pharmaceutical-grade quality standards
Sobo approaches weight loss as long-term metabolic care
Early treatment vs dose escalation patterns Why symptoms improve in some patients but persist in others Symptom patterns vary because of differences in gastric sensitivity, meal composition, eating behaviors , and individual response to GLP-1mediated motility changes
